


# Atlantic Collaborative Recommendations for Managing the Bleeding Patient on Apixaban, Dabigatran or Rivaroxaban

## Pharmacologic Properties of Apixaban, Dabigatran & Rivaroxaban

	Apixaban <sup>7</sup>	Dabigatran <sup>8</sup>	Rivaroxaban <sup>5</sup>
<b>Peak level</b>	3 – 4 hours	2 hours	1.5 - 4 hours
<b>Renal clearance</b>	27%	80%	66 %
<b>Half-life</b>	12 hours	11-17 hours	5 - 9 hours
	(longer in elderly and patients with renal dysfunction)		

### Assessment of Bleeding Patient Receiving Apixaban, Dabigatran or Rivaroxaban

There is limited clinical data related to reversal of apixaban, dabigatran and rivaroxaban. With no proven antidote available at the current time, the recommendations below may change as new evidence becomes available.



The anticoagulant effect of apixaban, dabigatran or rivaroxaban will not be reversed by the administration of vitamin K or plasma infusion.<sup>1</sup> **DO NOT TRANSFUSE PLASMA** to reverse an elevated aPTT or INR.

There is insufficient evidence to recommend the use of Prothrombin Complex Concentrates (octaplex® or Beriplex®P/N), FEIBA or rFVIIa (NiaStase®) for the reversal of these medications.<sup>4</sup>

In overdose situations without bleeding, activated charcoal may be considered for apixaban, dabigatran and rivaroxaban. Hemodialysis may be considered for patients with renal failure while taking dabigatran however apixaban and rivaroxaban are not expected to be dialyzable.<sup>5, 7, 8</sup>

**Moderate to severe bleeding** – a reduction in Hgb ≥ 20g/L, symptomatic bleeding in an organ or critical area, e.g. intraocular, intracranial, intramuscular, retroperitoneal, intra-articular or pericardial bleeding.<sup>1</sup>

**Life-threatening bleeding** – a reduction in Hgb ≥ 50g/L, symptomatic intracranial bleed, hypotension requiring inotropic agents, e.g. dopamine, bleeding requiring surgery.<sup>1</sup>

#### References:

1. New Zealand Government, PHARMAC (Pharmaceutical Management Agency) <http://www.pharmac.govt.nz/2011/06/13/Dabigatran%20bleeding%20management.pdf>
2. Sunnybrook Medical Centre, 2011. Management of the bleeding patient receiving Dabigatran
3. Best Practice Journal, 2011. The use of dabigatran in general practice: a cautious approach is recommended - <http://www.bpac.org.nz/magazine/2011/september/dabigatran.asp>
4. National Advisory Committee on Blood and Blood Products, 2011. Direct Thrombin Inhibitors
5. Bayer Inc., 2013 Xarelto® Product Monograph
6. Government of Saskatchewan, 2012. Directive on the care of the Patient with Bleeding on Dabigatran Therapy
7. Bristol-Myers Squibb Inc., 2012. Eliquis™ Product Monograph
8. Boehringer Ingelheim Canada Ltd., 2012. Pradax™ Product Monograph